Mirikizumab Side Effects
Medically reviewed by Drugs.com. Last updated on Jan 23, 2024.
Applies to mirikizumab: solution.
Serious side effects of Mirikizumab
Along with its needed effects, mirikizumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking mirikizumab:
More common
- Body aches or pain
- chills
- cough
- diarrhea
- ear congestion
- fever
- headache
- loss of taste or smell
- loss of voice
- muscle pain
- nausea or vomiting
- sneezing
- sore throat
- stuffy or runny nose
- trouble breathing
- unusual tiredness or weakness
Less common
- Burning or stinging of the skin
- painful blisters on the trunk of body
- painful cold sores or blisters on the lips, nose, eyes, or genitals
Incidence not known
- Chest tightness
- dark urine
- difficulty swallowing
- fast heartbeat
- hives, itching, skin rash
- loss of appetite
- lower back or side pain
- painful or difficult urination
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- stomach pain, severe
- yellow eyes or skin
Other side effects of Mirikizumab
Some side effects of mirikizumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
Less common
- Difficulty in moving
- joint pain
- muscle pain or stiffness
For Healthcare Professionals
Applies to mirikizumab: intravenous solution, subcutaneous solution.
General
The most common adverse reactions reported are upper respiratory tract infection, headache, rash, and injection site reactions.[Ref]
Cardiovascular
Common (1% to 10%): Hypertension[Ref]
Dermatologic
Common (1% to 10%): Rash[Ref]
Rash included macular rash, maculopapular rash, pruritic rash, and popular rash.[Ref]
Gastrointestinal
Common (1% to 10%): Ulcerative colitis, abdominal pain, diarrhea, gastroesophageal reflux disease
Frequency not reported: Intestinal sepsis[Ref]
Hematologic
Common (1% to 10%): Anemia[Ref]
Hepatic
Uncommon (0.1% to 1%): Increased AST, increased ALT[Ref]
Immunologic
Very common (10% or more): Anti-drug antibodies (up to 23%)[Ref]
Local
Common (1% to 10%): Injection site reactions[Ref]
Injection site reactions included erythema, hypersensitivity, pain, reaction, and urticaria at the injection site.[Ref]
Musculoskeletal
Common (1% to 10%): Arthralgia[Ref]
Other
Common (1% to 10%): Herpes viral infection, pyrexia, increased blood creatine phosphokinase, fatigue
Frequency not reported: Listeria sepsis[Ref]
Herpes viral infection included herpes zoster, herpes simplex, and oral herpes.[Ref]
Nervous system
Common (1% to 10%): Headache[Ref]
Respiratory
Very common (10% or more): Upper respiratory tract infections (up to 14%)
Frequency not reported: Pneumonia[Ref]
Upper respiratory tract infections included COVID-19, nasopharyngitis, pharyngitis, rhinitis, oropharyngeal discomfort, oropharyngeal pain, tonsillitis, viral upper respiratory tract infection, acute sinusitis, and sinusitis.[Ref]
More about mirikizumab
- Check interactions
- Compare alternatives
- Dosage information
- During pregnancy
- Drug class: interleukin inhibitors
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
References
1. Product Information. Omvoh (mirikizumab). Lilly, Eli and Company. 2023;1.0.
2. Product Information. Omvoh (mirikizumab). Eli Lilly and Company Ltd. 2023.
3. Product Information. Omvoh (mirikizumab). Eli Lilly Australia Pty Ltd. 2023.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.